The latest price target for Arrowhead Pharma (NASDAQ:ARWR) was reported by B. Riley Securities on February 14, 2025. The analyst firm set a price target for $38.00 expecting ARWR to rise to within 12 months (a possible 90.95% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Arrowhead Pharma (NASDAQ:ARWR) was provided by B. Riley Securities, and Arrowhead Pharma reiterated their buy rating.

The last upgrade for Arrowhead Pharmaceuticals Inc happened on April 12, 2023 when SVB Securities raised their price target to $35. SVB Securities previously had a market perform for Arrowhead Pharmaceuticals Inc.

The last downgrade for Arrowhead Pharmaceuticals Inc happened on May 12, 2023 when SVB Leerink changed their price target from N/A to $40 for Arrowhead Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arrowhead Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arrowhead Pharma was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.

While ratings are subjective and will change, the latest Arrowhead Pharma (ARWR) rating was a reiterated with a price target of $51.00 to $38.00. The current price Arrowhead Pharma (ARWR) is trading at is $19.90, which is out of the analyst’s predicted range.